MedTrace Logo

Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)

NCT00935285 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2009-07-09

No results posted yet for this study

Summary

Ventilator-associated pneumonia (VAP) is very common in the intensive care unit (ICU), affecting 9 to 40% of ICU patients and mortality rates range from 20 to 50% and may reach more than 70% when the infection is caused by multi-resistant and invasive pathogens. The most common pathogens that cause VAP are the Gram(-) bacteria. Findings indicate that TLRs serves as an important signal in the generation of protective innate responses to bacterial pathogens of the lung and that is required for effective innate immune responses against Gram-negative bacterial pathogens. There is genetic evidence that mutations in TLRs increase the risk of developing nosocomial infections. Understanding the TLR system should offer invaluable opportunity for manipulating host immune responses.

Conditions

  • Ventilator-Associated Pneumonia

Sponsors & Collaborators

  • University of Thessaly

    lead OTHER

Principal Investigators

  • Sofia Sarafi RN MSc, ICU · University Hospital Larisa

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935285 on ClinicalTrials.gov